AffaMed Therapeutics
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
450 Lexington Ave Ste 39B, New York City...Phone Number
(450) 810-0004Website
www.affamed.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About AffaMed Therapeutics
AffaMed Therapeutics is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products that address significant unmet medical needs in ophthalmology. The company focuses on a range of clinical assets aimed at treating various ophthalmic conditions, including ocular inflammation and pain following surgery, as well as allergic conjunctivitis. AffaMed aims to provide its transformative solutions to patients in Greater China and globally. With a strong leadership team and extensive global network, the company is committed to bridging the gap between unmet patient needs and effective treatments.Explore more
AffaMed Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AffaMed Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once AffaMed Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
AffaMed Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on AffaMed Therapeutics recently announced quarterly report
Click to see if AffaMed Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when AffaMed Therapeutics launches new products
Check out if AffaMed Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at AffaMed Therapeutics
Check if AffaMed Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to AffaMed Therapeutics
Compare insights from companies similar to AffaMed Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AffaMed Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AffaMed Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AffaMed Therapeutics.
AffaMed Therapeutics financials insights
Gather financial insights about AffaMed Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$170M
AffaMed Therapeutics Tech Stack
A closer look at the technologies used by AffaMed Therapeutics
AffaMed Therapeutics News & Media
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery
SHANGHAI, Oct. 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, announced positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of DEXTENZA® (0.4 mg dexamethaAffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL
Expands Portfolio of Cataract Surgery Solutions for Patients in Greater China to New Extended Monofocal Segment AffaMed Therapeutics and SIFI Leadership Celebrate Strong Progress of the AffaMed Technologies Joint-Venture BEIJING, Oct. 10, 2023 /PRNewswire/ -- AffaMed Technologies ("AffaMed"), a joint venture established between AffaMed Therapeutics and SIFI S.p.A. ("SIFI"), today announced it has entered into a licensing agreement with SIFI under which AffaMed has obtained the exclusive rights tAffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, today announced that China's National Medical Products Administration has approved AffaMed's Clinical Trial Application (CTA) to investigate the efficacy and safety of Risuteganib (LuminAffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmologic, neurological and psychiatric disorders, today announced that the first patient has been treated in the Phase 3 registrational study in China to investigate the efficacy and safety of DEXTENZA (0.4 mg dexamethasone ophthalmic ins
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AffaMed Therapeutics
Sign Up For FreeTo access detailed company insights
AffaMed Therapeutics is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products that address significant unmet medical needs in ophthalmology. The company focuses on a range of clinical assets aimed at treating various ophthalmic conditions, including ocular inflammation and pai... Read More
